In von Willebrand disease, which of the following is NOT a recommended treatment?

In von Willebrand disease, which of the following is NOT a recommended treatment?

• A. Cryoprecipitate
• B. Fresh frozen plasma
• C. Factor VIII concentrates
• D. Recombinant factor VIII

Answer: (D)

In von Willebrand disease the problem is a deficiency or dysfunction of von Willebrand factor, which is crucial for platelet adhesion and also stabilizes factor VIII. Treatments aim to restore or replace vWF (and, when needed, support FVIII levels). Recombinant factor VIII provides only FVIII without any von Willebrand factor, so it does not address the core defect in VWD. Without vWF, platelet adhesion remains impaired and FVIII can be unstable, so bleeding risk isn’t adequately corrected. That’s why recombinant factor VIII is not recommended for treating von Willebrand disease. In contrast, products that supply vWF, such as cryoprecipitate or vWF-containing factor concentrates, or even fresh frozen plasma when other options aren’t available, can help correct the underlying deficiency.

In von Willebrand disease the problem is a deficiency or dysfunction of von Willebrand factor, which is crucial for platelet adhesion and also stabilizes factor VIII. Treatments aim to restore or replace vWF (and, when needed, support FVIII levels). Recombinant factor VIII provides only FVIII without any von Willebrand factor, so it does not address the core defect in VWD. Without vWF, platelet adhesion remains impaired and FVIII can be unstable, so bleeding risk isn’t adequately corrected. That’s why recombinant factor VIII is not recommended for treating von Willebrand disease. In contrast, products that supply vWF, such as cryoprecipitate or vWF-containing factor concentrates, or even fresh frozen plasma when other options aren’t available, can help correct the underlying deficiency.